INFINIUMPharmaceuticals
Infinium Pharmachem Ltd — Profit & Loss Statement
₹192.80
-0.37%
Infinium Pharmachem Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | -0.06 Cr | -0.02 Cr | — |
| Tax Rate For Calcs | 0.32 | 0.24 | 0.24 | 0.23 | — |
| Normalized EBITDA | 18.54 Cr | 20.07 Cr | 17.33 Cr | 10.81 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | -0.24 Cr | -0.11 Cr | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | -0.24 Cr | -0.11 Cr | — |
| Net Income From Continuing Operation Net Minority Interest | 8.15 Cr | 11.30 Cr | 9.49 Cr | 6.11 Cr | — |
| Reconciled Depreciation | 3.29 Cr | 2.67 Cr | 1.34 Cr | 0.63 Cr | — |
| Reconciled Cost Of Revenue | 117.60 Cr | 103.10 Cr | 80.57 Cr | 76.74 Cr | — |
| EBITDA | 18.54 Cr | 20.07 Cr | 17.09 Cr | 10.70 Cr | — |
| EBIT | 15.24 Cr | 17.40 Cr | 15.75 Cr | 10.07 Cr | — |
| Net Interest Income | -3.67 Cr | -2.19 Cr | -3.09 Cr | -1.67 Cr | — |
| Interest Expense | 3.67 Cr | 2.19 Cr | 2.79 Cr | 1.44 Cr | — |
| Normalized Income | 8.15 Cr | 11.30 Cr | 9.67 Cr | 6.19 Cr | — |
| Net Income From Continuing And Discontinued Operation | 8.15 Cr | 11.30 Cr | 9.49 Cr | 6.11 Cr | — |
| Total Expenses | 142.58 Cr | 119.80 Cr | 99.27 Cr | 89.60 Cr | — |
| Diluted NI Availto Com Stockholders | 8.15 Cr | 11.30 Cr | 9.49 Cr | 6.11 Cr | — |
| Net Income Common Stockholders | 8.15 Cr | 11.30 Cr | 9.49 Cr | 6.11 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 8.15 Cr | 11.30 Cr | 9.49 Cr | 6.11 Cr | — |
| Minority Interests | 0.30 Cr | -0.20 Cr | -0.33 Cr | -0.58 Cr | — |
| Net Income Including Noncontrolling Interests | 7.84 Cr | 11.50 Cr | 9.82 Cr | 6.69 Cr | — |
| Net Income Continuous Operations | 7.84 Cr | 11.50 Cr | 9.82 Cr | 6.69 Cr | — |
| Tax Provision | 3.73 Cr | 3.71 Cr | 3.14 Cr | 1.95 Cr | — |
| Pretax Income | 11.57 Cr | 15.21 Cr | 12.95 Cr | 8.63 Cr | — |
| Other Non Operating Income Expenses | 2.12 Cr | 1.54 Cr | 0.33 Cr | 0.68 Cr | — |
| Special Income Charges | 0.00 | 0.00 | -0.24 Cr | -0.11 Cr | — |
| Net Non Operating Interest Income Expense | -3.67 Cr | -2.19 Cr | -3.09 Cr | -1.67 Cr | — |
| Interest Expense Non Operating | 3.67 Cr | 2.19 Cr | 2.79 Cr | 1.44 Cr | — |
| Operating Income | 13.13 Cr | 15.86 Cr | 14.96 Cr | 9.52 Cr | — |
| Operating Expense | 24.98 Cr | 16.70 Cr | 18.70 Cr | 12.86 Cr | — |
| Other Operating Expenses | 14.26 Cr | 8.12 Cr | 10.05 Cr | 6.42 Cr | — |
| Depreciation And Amortization In Income Statement | 3.29 Cr | 2.67 Cr | 1.34 Cr | 0.63 Cr | — |
| Depreciation Income Statement | 3.29 Cr | 2.67 Cr | 1.34 Cr | 0.63 Cr | — |
| Gross Profit | 38.11 Cr | 32.55 Cr | 33.65 Cr | 22.38 Cr | — |
| Cost Of Revenue | 117.60 Cr | 103.10 Cr | 80.57 Cr | 76.74 Cr | — |
| Total Revenue | 155.71 Cr | 135.66 Cr | 114.22 Cr | 99.12 Cr | — |
| Operating Revenue | 155.71 Cr | 135.66 Cr | 114.22 Cr | 99.12 Cr | — |
| Interest Income | — | 0.18 Cr | 0.02 Cr | 0.03 Cr | 0.02 Cr |
| Diluted Average Shares | — | 1.07 Cr | 1.39 Cr | 1.39 Cr | 1.39 Cr |
| Basic Average Shares | — | 1.07 Cr | 1.39 Cr | 1.39 Cr | 1.39 Cr |
| Diluted EPS | — | 10.61 | 6.82 | 4.39 | 1.96 |
| Basic EPS | — | 10.61 | 6.82 | 4.39 | 1.96 |
| Net Income Discontinuous Operations | — | 0.00 | 0.00 | 0.00 | 0.00 |
| Impairment Of Capital Assets | — | 0.04 Cr | 0.02 Cr | — | — |
| Total Other Finance Cost | — | 0.30 Cr | 0.31 Cr | 0.26 Cr | 0.24 Cr |
| Interest Income Non Operating | — | 0.18 Cr | 0.02 Cr | 0.03 Cr | 0.02 Cr |
| Selling General And Administration | — | 2.04 Cr | 1.95 Cr | 2.28 Cr | 1.07 Cr |
| Selling And Marketing Expense | — | 1.20 Cr | 0.82 Cr | 1.10 Cr | 0.40 Cr |
| General And Administrative Expense | — | 0.84 Cr | 1.13 Cr | 1.18 Cr | 0.67 Cr |
| Other Special Charges | — | — | 0.22 Cr | — | — |
| Write Off | — | — | — | 0.11 Cr | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Infinium Pharmachem Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.